Abstract
The presence of bone metastases predicts the presence of pain and is the most common cause of cancer-related pain. Although bone metastases do not involve vital organs, they may determine deleterious effects in patients with prolonged survival. Bone fractures, hypercalcaemia, neurologic deficits and reduced activity associated with bone metastases result in an overall compromise in the patient’s quality of life. A metastasis is a consequence of a cascade of events including a progressive growth at the primary site, vascularization phase, invasion, detachment, embolization, survival in the circulation, arrest at the site of a metastasis, extravasion, evasion of host defense and progressive growth. Once cancer cells establish in the bone, the normal process of bone turnover is disturbed. The different mechanisms responsible for osteoclast activation correspond to typical radiologic features showing lytic, sclerotic or mixed metastases, according to the primary tumour. The release of chemical mediators, the increased pressure within the bone, microfractures, the stretching of periosteum, reactive muscle spasm, nerve root infiltration and compression of nerves by the collapse of vertebrae are the possible mechanisms of malignant bone pain. Pain is often disproportionate to the size or degree of bone involvement. The use of analgesics according to the WHO ladder is recommended. The difficulty with incident pain is not a lack of response to systemic opioids, but rather that the doses required to control the incidental pain produce unacceptable side effects at rest. Opioids should be carefully used to balance background analgesia and breakthrough pain. Once analgesic optimization is achieved there are several options to treat breakthrough pain, including opioids with a fast onset.
Invasive techniques are rarely indicated, but may provide analgesia in the treatment of pain resistant to the other modalities. Careful appraisal and the application of a correct approach should enable the patient with bone metastases to obtain an acceptable pain relief despite the advanced nature of their malignant disease.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mercadante S, Fulfaro F (2007) Management of painful bone metastases. Curr Opin Oncol 19:308–314
Clare C, Royle D, Saharia K, Pearse H et al (2005) Painful bone metastases: a prospective observational cohort study. Palliat Med 19:521–525
Wu J, Beaton D, Smith P, Hagen N (2010) Patterns of pain and interference in patients with painful bone metastases: a brief pain inventory validation study. J Pain Symptom Manage 39:230–240
Chow E, Doyle M, Li K, Bradley N et al (2006) Mild, moderate, or severe pain categorized by patients with cancer with bone metastases. J Palliat Med 9:850–854
Colvin L, Fallon M (2008) Challenges in cancer pain management-bone pain. Eur J Cancer 44:1083–1090
Jane SW, Wilkie DJ, Gallucci BB, Beaton RD, Huang HY (2009) Effects of a full-body massage on pain intensity, anxiety, and physiological relaxation in Taiwanese patients with metastatic bone pain: a pilot study. J Pain Symptom Manage 37:754–763
Mercadante S, Fulfaro F (2005) World Health Organization guidelines for cancer pain: a reappraisal. Ann Oncol 16(Suppl 4):iv132–135
Caraceni A, Hanks G, Kaasa S et al (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13:e58–68
Mercadante S (2001) The use of NSAIDs in cancer pain. Cancer Treat Rev 27:51–61
Mercadante S, Fulfaro F, Casuccio A (2002) A randomised controlled study on the use of anti-inflammatory drugs in patients with cancer on morphine therapy: effect on dose-escalation and pharmacoeconomic analysis. Eur J Cancer 38:1358–1363
Tassinari D, Drudi F, Rosati M et al (2011) The second step of the analgesic ladder and oral tramadol in the treatment of mild to moderate cancer pain: a systematic review. Palliat Med 25:410–423
Mercadante S, Porzio G, Ferrera P et al (2006) Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage 31:242–247
Mercadante S, Bruera E (2006) Opioid switching: a systematic and critical review. Cancer Treat Rev 32:304–315
Klepstad P, Kaasa S, Borchgrevink P (2011) Starting step III opioids for moderate to severe pain in cancer patients: dose titration: a systematic review. Palliat Med 25:424–430
Mercadante S, Arcuri E (2004) Opioids and renal function. J Pain 5:2–19
King S, Forbes K, Hanks GW, Ferro CJ, Chambers EJ (2011) A systematic review of the use of opioid medication for those with moderate and severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines projects. Palliat Med 25:525–552
Mercadante S, Caraceni A (2011) Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med 25:504–515
Kress HG (2010) Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain 14:781–783
Mercadante S, Porzio G, Ferrera P (2012) Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin. 28:1775–9
Mercadante S, Villari P, Ferrera P et al (2002) Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer 95:203–208
Lasheen W, Walsh D, Manhmoud F (2010) The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer pain. Palliat Med 24:9–16
Tassinari D, Drudi F, Rosati M, Maltoni M (2011) Transdermal opioids as front line treatment of moderate to severe cancer pain: a systematic review. Palliat Med 25:478–487
Laugsand E, Kaasa S, Klepstad P (2011) Management of opioid-induced nausea and vomiting in cancer patients: systematic review and evidence-based recommendations. Palliat Med 25:442–453
Stone P, Minton O (2011) European Palliative Care Research collaborative guidelines. Central side-effects management: what is the evidence to support best practice in the management of confusion, cognitive impairment and myoclonus? Palliat Med 25:431–441
Druney J, Ross J, Gretton S, Welsh K, Sato H, Riley J (2008) Constipation in cancer patients on morphine. Support Care Cancer 16:453–459
Meissner W, Leyendecker P, Mueller-Lissner S et al (2009) A randomized controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 13:56–64
Ahmedzai SH, Nauck F, Bar-Sela G (2012) A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 26:50–60
Iskedjian M, Iyer S, Librach L et al (2011) Methylnaltrexone in the treatment of opioid-induced constipation in cancer patients receiving palliative care: willingness-to-pay and cost-benefit analysis. J Pain Symptom Manage 41:104–115
Dale O, Maksnes K, Kaasa S (2011) European Palliative Care Research Collaborative pain guidelines: opioid switching to improve analgesia or reduce side effects. A Syst Rev 25:494–503
Portenoy RK, Payne D, Jacobsen P (1999) Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81:129–134
Mercadante S, Villari P, Ferrera P, Casuccio A (2004) Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manage 28:505–510
Zeppetella G (2009) Dynamics of breakthrough pain vs pharmacokinetics of oral morphine: implications for management. Eur J Cancer Care 18:331–337
Mercadante S (2011) The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit Rev Hematol Oncol 80:460–465
Mercadante S (2012) Pharmacotherapy for breakthrough cancer pain. Drugs 72:181–190
Davies AD, Dickman A, Reid C, Stevens A, Zeppetella G (2009) The management of cancer-related breakthrough pain: recommendations of a task group of the science committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 13:331–338
Davies AN, Vriens J, Kennett A, McTaggart M (2008) An observational study of oncology patients’ utilization of breakthrough pain medication. J Pain Symptom Manage 35:406–411
Zeppetella GB (2008) Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage 35:563–567
Hagen NA, Fisher K, Victorino C, Farrar JT (2007) A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. J Palliat Med 10:47–55
Mercadante S, Gatti A, Porzio G et al (2012) Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Curr Med Res Opin 28:963–968
Peters C, Ghilardi J, Geyser C et al (2005) Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain. Exp Neurol 193:85–100
Kerba M, Wu JS, Duan Q, Hagen NA, Bennett MI (2010) Neuropathic pain features in patients with bone metastases referred for palliative radiotherapy. J Clin Oncol 28:4892–4897
Caraceni A, Zecca E, Martini C et al (2008) Gabapentin for breakthrough pain due to bone metastases. Palliat Med 22:392–393
Portenoy RK (2011) Treatment of cancer pain. Lancet 377:2236–2247
Berger A, Dukes E, Mercadante S et al (2006) Use of antiepileptics and tricyclic antidepressants in cancer patients with neuropathic pain. Eur J Cancer Care 15:138–145
Mercadante S, Porzio G, Gebbia V (2012) Spinal analgesia for advanced cancer patients: an update. Crit Rev Hematol Oncol 82:227–232
Mercadante S, Intravaia G, Villari P et al (2007) Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J Pain 23:793–798
Kurup AN, Callstrom MR (2010) Ablation of skeletal metastases: current status. J Vasc Interv Radiol 21(8 Suppl):S242–250
Eck JC, Nachtigall D, Humphreys SC, Hodges SD (2008) Comparison of Vertebroplasty and Balloon Kyphoplasty for treatment of vertebral compression fractures: a meta-analysis of the literature. Spine 8:488–497
Berenson J, Pflugmacher R, Jarzem P et al (2011) Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomized controlled trial. Lancet Oncol 12:225–235
Kallmes DF, Comstock BA, Heagerty PJ et al (2009) A randomized trial of vertebroplasty for osteoporotic spinal fractures. N Engl J Med 361:569–579
Wardlaw D, Cummings SR, Van Meirhaeghe J et al (2009) Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet 373:1016–1024
Callstrom MR, Charboneau JW (2007) Image-guided palliation of painful metastases using percutaneous ablation. Tech Vasc Interv Radiol 10:120–131
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Mercadante, S. (2014). Analgesic Treatment of Bone Metastases. In: Vassiliou, V., Chow, E., Kardamakis, D. (eds) Bone Metastases. Cancer Metastasis - Biology and Treatment, vol 21. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7569-5_8
Download citation
DOI: https://doi.org/10.1007/978-94-007-7569-5_8
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-7568-8
Online ISBN: 978-94-007-7569-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)